The FDA has approved two additional configurations of Infuse Bone Graft – XX Small (0.7cc) kit and X Small (1.4cc) kit. These new sizes will be available for clinical use in June, 2008.
Infuse Bone Graft is recombinant human bone morphogenetic protein-2 (rhBMP-2) applied to an absorbable collagen sponge carrier. The purpose of the protein, which occurs naturally in the body, is to stimulate bone formation.
Doug King, vice president Sales, Medtronic’s Spinal and Biologics business, said: “Since its initial market introduction, Infuse Bone Graft has enabled advances in surgical procedures and been used successfully in treating over 500,000 patients.”